A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Patients With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib (REACH)
This study is ongoing, but not recruiting participants.
Sponsor:
ImClone LLC
Information provided by (Responsible Party):
ImClone LLC
ClinicalTrials.gov Identifier:
NCT01140347
First received: June 2, 2010
Last updated: April 18, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is ongoing, but not recruiting participants. |
|---|---|
| Estimated Study Completion Date: | July 2015 |
| Estimated Primary Completion Date: | March 2014 (Final data collection date for primary outcome measure) |
| Certification or Request for Extension to Delay Results Received: | July 29, 2010 |